Information Provided By:
Fly News Breaks for December 6, 2016
PCRX
Dec 6, 2016 | 08:08 EDT
Jefferies analyst David Steinberg says his firm's survey of 50 high volume clinicians suggests gradually improving utilization in 2017 for Pacira Pharmaceuticals' Exparel. The survey results are more encouraging than a year ago, Steinberg tells investors in a research note. He keeps a Buy rating on Pacira with a $53 price target.
News For PCRX From the Last 2 Days
There are no results for your query PCRX